T. Rowe Price Associates’s Zevra Therapeutics ZVRA Stock Holding History

T. Rowe Price Associates’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$694K	Buy	48,379 +4,763	+11%	+$52.9K	﹤0.01%	2473
2026 Q1	$407K	Buy	43,616 +11,476	+36%	+$103K	﹤0.01%	2540
2025 Q4	$288K	Buy	32,140 +3,648	+13%	+$34.5K	﹤0.01%	2663
2025 Q3	$271K	Buy	28,492 +2,802	+11%	+$28.1K	﹤0.01%	2652
2025 Q2	$227K	Buy	25,690 +3,005	+13%	+$24.4K	﹤0.01%	2660
2025 Q1	$170K	Buy	22,685 +2,120	+10%	+$16.8K	﹤0.01%	2707
2024 Q4	$172K	Buy	20,565 +6,966	+51%	+$59.5K	﹤0.01%	2741
2024 Q3	$95K	Hold	13,599	–	–	﹤0.01%	2828
2024 Q2	$67K	Buy	13,599 +2,588	+24%	+$12.3K	﹤0.01%	2816
2024 Q1	$64K	Buy	+11,011	New	+$67.7K	﹤0.01%	2841

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's ZVRA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Zevra Therapeutics (ZVRA) stake by 11% in Q2 2026, buying an estimated $52.9K and bringing the position to 48,379 shares worth $694K. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

T. Rowe Price Associates first reported a position in ZVRA in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

T. Rowe Price Associates held 48,379 shares of Zevra Therapeutics worth $694K as of Q2 2026.
T. Rowe Price Associates bought 4,763 Zevra Therapeutics shares in Q2 2026, an estimated $52.9K.
Zevra Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2473 holding.
T. Rowe Price Associates first reported a position in Zevra Therapeutics in Q1 2024 and has held it in 10 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.